Larotrectinib is approved by NICE as an option for NTRK fusion-positive solid tumours Picture: iStock Essential facts Larotrectinib is one of a new breed of cancer drugs designed to target specific changes in the DNA of cancer cells, rather than where the disease is growing in the body. This means patients, including children, with various cancer types may benefit from its use. It is particularly useful for those patients at an advanced stage of cancer, when other options are limited or have been exhausted.
In major medical advancement, study finds additional chemo slashes risk of cervical cancer death - Good Morning America
Cancer Treatment and Cardiotoxicity: Best Ways To Protect Your Heart
TGen News & Press Releases : TGen-UArizona medical school study points to possible new treatment options for breast cancer patients
Clinical update, Cancer Nursing Practice
Why Do Cancer Treatments Stop Working? - NCI
CAR T Cell Therapy: A remarkable breakthrough in cancer treatment
Cancer Nursing Practice
Frontiers Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches
Clinical update, Cancer Nursing Practice
More time is more hope
Clinical update, Cancer Nursing Practice
